CXCR2 inhibitors

Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S367000

Reexamination Certificate

active

07919628

ABSTRACT:
The invention relates to compounds of the formula I:in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

REFERENCES:
patent: 2002/0123522 (2002-09-01), Fritz et al.
patent: WO99/07351 (1999-02-01), None
Kubinyi (3D QSAR in Drug Design: Ligand-Protein Interactions and Molecular Similarity, vol. 2-3, Springer, 1998, 800 pages); pp. 243-244 provided.
CAPLUS Abstract of: Jodlbauer et al. (J. Chromatography, A (2002), 945(1-2), 45-63).
Boschelli et al., Inhibition of E-Selectin-, ICAM-1-, and VCAM-1-Mediated Cell Adhesion by Benzo(b)thiophene-, Benzofuran-, Indole-, and Naphthalene-2-carboxamides: Identification of PD 144795 as a Antiinflammatory Agent, J. Med. Chem., vol. 38 (1995, pp. 4597-4614.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

CXCR2 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CXCR2 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CXCR2 inhibitors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2640266

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.